Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPER trial of perioperative nivolumab versus surgery and surveillance in localized kidney cancer
MOH_2018-02-19_000743Phase 3Not yet recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in renal cell carcinoma (RCC) (2 arms), sponsored by ECOG-ACRIN Cancer Research Group. Planned start Nov 2017; status: not yet recruiting.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on MOH_2018-02-19_000743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-02-19_000743.